Dermata Therapeutics Inc (DRMA NASDAQ) stock market data APIs
$0.8316
-0.06(-7.2%)
as of May 19, 2025
Try our APIs with
free plan!
Dermata Therapeutics Inc Financial Data Overview
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its lead product candidate is XYNGARI, which is in Phase 3 clinical studies for the treatment of moderate-to-severe acne, as well as completed Phase 1b proof of concept (POC) trial for mild-to-moderate psoriasis. The company is also developing DMT410 that has completed Phase 1b POC trials for the treatment of axillary hyperhidrosis and aesthetic skin conditions. It has a clinical trial collaboration agreement with Revance Therapeutics, Inc. to conduct a multi-center clinical trial to evaluate the topical application of XYNGARI with DAXXIFY, Revance's botulinum toxin type A. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Prev. Close
0.8316
Open
0.7703
High
0.8325
Low
0.7703
52 wk Range
0.69-3.92
Market Cap
4 507 K
Shares Outstanding
5 431 K
EPS
-1.2515
Beta
0.59
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Dermata Therapeutics Inc data using free add-ons & libraries
Get Dermata Therapeutics Inc Fundamental Data
Dermata Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -7 856 542
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-07
- EPS/Forecast: -0.45
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Dermata Therapeutics Inc News
New
7 F-Rated Growth Stocks to Avoid Like the Plague in August 2024
What do you call a growth stock that isn’t growing any more? The answers are many. You can call it a disappointment. A drain on your portfolio. A bad investment. Any of these are true of F-rated gr...
Presenting on the Emerging Growth Conference 69 Day 2 on April 4 Register Now
Emerging Growth MIAMI, April 03, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 69th Emerging Growth Conference on April 3 & 4,...
Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now
Emerging Growth MIAMI, April 02, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 69th Emerging Growth Conference on April 3 & 4,...
NKGen Biotech and Graf Acquisition Corp. IV Announce the Nomination of Two Independent Directors for the Board of Directors of the Post-Business Combination Public Company
SANTA ANA, Calif. and THE WOODLANDS, Texas, Aug. 09, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
